MAIA Biotechnology Expects $33M In Proceeds From Public Offering To Fully Fund Phase 3 Clinical Trial For Non-Small Cell Lung Cancer Treatment Ateganosine

MAIA Biotechnology, Inc. +6.67%

MAIA Biotechnology, Inc.

MAIA

1.28

+6.67%

MAIA Biotechnology Expects $33M In Proceeds From Public Offering To Fully Fund Phase 3 Clinical Trial For Non-Small Cell Lung Cancer Treatment Ateganosine